MannKind | MNKD - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
Adma Biologics USD 62.75M 11.74M 2025-12
BioCryst Pharmaceuticals USD 260.38M 230.79M 2025-12
Eli Lilly USD 8.99B 599.9M 2025-12
Halozyme Therapeutics USD -88.41M 306.33M 2025-12
Insmed USD -249.71M 11.64M 2025-12
Karyopharm Therapeutics USD -31.28M 5M 2024-12
MacroGenics USD -12.1M 30.74M 2025-12
MannKind USD -69.24M 28.19M 2025-12
Merck USD 6.24B 318M 2025-12
Minerva Neurosciences USD -21.85M 17.48M 2024-12
Novavax USD 20.94M 100.32M 2025-12
Novo Nordisk DKK 5.18B 33.61B 2025-06
Pfizer USD 4.65B 3.99B 2025-12
Sanofi EUR 1.7B 2.17B 2025-12
Xencor USD -53.63M 6.11M 2025-12